PDF(Pubmed)
Abstract：
Teduglutide is a glucagon-like peptide 2 (GLP-2) analog which acts by increasing intestinal absorption of the remnant bowel for children with short bowel syndrome (SBS) dependent on parenteral nutrition. We present a 13-year-old male patient with type 2 SBS (55 cm of jejunum) from necrotizing enterocolitis on full oral feeding from the age of 12 months. Because of faltering growth from the age of 11 despite oral hyperphagia, he started Teduglutide at the standard dose. Eighteen months after Teduglutide start the young boy gained 10 kg in weight and 13 cm in height with a significant reduction in bowel distension. No adverse events were reported during the treatment. Pubertal spurt might be impaired in children with SBS on full oral feeding if the caloric need is not met by the residual intestinal absorption rate. GLP-2 analog might represent an option to sustain pubertal spurt in SBS children on full oral feeding with hyperphagia.
摘要：
Teduglutide是胰高血糖素样肽2（GLP-2）类似物，其作用是增加依赖于肠胃外营养的短肠综合征（SBS）儿童的残余肠的肠吸收。我们介绍了一名13岁的男性患者，患有坏死性小肠结肠炎的2型SBS（空肠55厘米），从12个月大开始完全口服喂养。尽管口食过多，但从11岁开始生长步履蹒跚，他从标准剂量开始服用Teduglutide.Teduglutide开始18个月后，这个小男孩的体重增加了10公斤，身高增加了13厘米，肠扩张显着减少。治疗期间未报告不良事件。如果残余的肠吸收率不能满足热量需求，则完全口服喂养的SBS儿童可能会损害青春期突增。GLP-2类似物可能代表一种选择，可以在SBS儿童中进行完全口服喂养并伴有吞食过多的情况下维持青春期突增。
